From Nasdaq: 2024-05-21 05:20:00

Sanofi partners with OpenAI and Formation Bio to develop AI-powered software to speed up drug development for new medicines. The collaboration aims to harness the positive impact of AI on patient treatment.

The deal will combine data, software, and AI models to create tailored solutions for drug development, marking a groundbreaking initiative in the pharma industry. Sanofi plans to use proprietary data to become an AI-powered biopharma company.

OpenAI, backed by Microsoft, will contribute cutting-edge AI capabilities, while Formation Bio will offer engineering resources and expertise in pharma and AI. The partnership will focus on designing and deploying AI technologies across the pharmaceutical lifecycle.

Sanofi’s CEO sees the collaboration as a significant step towards a future powered by AI in drug development. OpenAI’s COO highlights the potential of AI in accelerating drug development to benefit patients. The partnership aims to deliver innovative treatments for patients in need.

OpenAI recently partnered with Reddit to integrate ChatGPT into its products, expanding its reach. Additionally, Apple is reportedly in talks with OpenAI to incorporate ChatGPT features into iOS 18, further demonstrating the AI chatbot’s growing influence in technology.



Read more at Nasdaq: Sanofi, OpenAI To Build AI Software To Boost Drug Development